donepezil pamoate (HHT201)
/ Shanghai Synergy Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 18, 2024
A Single Dose Escalation Study of HHT201 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
New P1 trial • Alzheimer's Disease • CNS Disorders
September 29, 2020
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects
(clinicaltrials.gov)
- P1; N=38; Completed; Sponsor: Shanghai Synergy Pharmaceutical Sciences Co., Ltd.; Recruiting ➔ Completed
Clinical • Trial completion
May 27, 2020
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects
(clinicaltrials.gov)
- P1; N=38; Recruiting; Sponsor: Shanghai Synergy Pharmaceutical Sciences Co., Ltd.; Not yet recruiting ➔ Recruiting; N=18 ➔ 38; Trial completion date: May 2020 ➔ Oct 2020; Trial primary completion date: Mar 2020 ➔ Sep 2020
Clinical • Enrollment change • Enrollment open • Trial completion date • Trial primary completion date
1 to 3
Of
3
Go to page
1